PRL and breast carcinoma: Though early clinical studies of patients treated with bromocriptine, an inhibitor of pituitary PRL, found no association with breast cancer, recent evidence of autocrine/paracrine regulation [14,15] of PRL in extra-pituitary tissue provides further support for a possible role of PRL in tumorigenesis.